Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)

Maurizio Moretti (Modena, Italy), Maurizio Moretti

Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Session: Novel avenues in the treatment of COPD II
Session type: Thematic Poster
Number: 4077
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Maurizio Moretti (Modena, Italy), Maurizio Moretti. Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD). Eur Respir J 2016; 48: Suppl. 60, 4077

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Impact of mucolytic treatment on COPD exacerbations
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013

Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016


Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013


Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Mukoregulatory drugs in treating COPD
Source: International Congress 2014 – Predictors
Year: 2014


Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014

Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013


Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Cognitive impairment in patients hospitalized with acute COPD exacerbation
Source: International Congress 2014 – Physical activity, exercise and physiotherapy in COPD and asthma
Year: 2014


Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013



Impact of bronchiectasis on duration of hospitalization in patients with exacerbations of COPD
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015

QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013



Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Impact of frequent exacerbations in patients with COPD
Source: International Congress 2014 – Clinical presentations
Year: 2014


Effect of noninvasive ventilation on interleukin-8 in COPD exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013


Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001

Penetration of moxifloxacin in bronchial secretions in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013